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AbstrACt
Introduction Speciic phobias (intense, enduring fears of 
an object or situation that lead to avoidance and severe 
distress) are highly prevalent among children and young 
people. Cognitive–behavioural therapy (CBT) is a well-
established, effective intervention, but it can be time 
consuming and costly because it is routinely delivered 
over multiple sessions during several months. Alternative 
methods of treating severe and debilitating phobias in 
children are needed, like one-session treatment (OST), to 
reduce time and cost, and to prevent therapeutic drift and 
help children recover quickly. Our study explores whether 
(1) outcomes with OST are ‘no worse’ than outcomes with 
multisession CBT, (2) OST is acceptable to children, their 
parents and the practitioners who use it and (3) OST offers 
good value for money to the National Health Service (NHS) 
and to society.
Method A pragmatic, non-inferiority, randomised 
controlled trial will compare OST with multisession CBT-
based therapy on their clinical and cost-effectiveness. The 
primary clinical outcome is a standardised behavioural 
task of approaching the feared stimulus at 6 months 
postrandomisation. The outcomes for the within-trial 
cost-effectiveness analysis are quality-adjusted life years 
based on EQ-5D-Y, and individual-level costs based of 
the intervention and use of health and social service care. 
A nested qualitative evaluation will explore children’s, 
parents’ and practitioners’ perceptions and experiences 
of OST. A total of 286 children, 7–16 years old, with 
DSM-IV diagnoses of speciic phobia will be recruited 
via gatekeepers in the NHS, schools and voluntary youth 
services, and via public adverts.
Ethics and dissemination The trial received ethical 
approval from North East and York Research Ethics 
Committee (Reference: 17/NE/0012). Dissemination 
plans include publications in peer-reviewed journals, 
presentations in relevant research conferences, local 
research symposia and seminars for children and their 
families, and for professionals and service managers.
trial registration number ISRCTN19883421;Pre-results.
IntroduCtIon  
A specific phobia is an intense, enduring fear 
of an identifiable object or situation that leads 
to distress and avoidance.1 It is estimated that 
between 5% and 10% of children have a 
specific phobia severe enough to impact on 
their everyday functioning,2 but fewer than 
10% seek treatment, therefore, the average 
duration of phobias is 20 years.3 The psycho-
logical, developmental and medical impact 
of these phobias is significant, with higher 
rates of health service usage than most other 
anxiety disorders.4 Phobias in children can 
result in considerable academic difficulties,5 
strengths and limitations of this study
 Ź To our knowledge, this is the largest proposed treat-
ment study and economic evaluation of interven-
tions for childhood phobias to date.
 Ź Interventions are delivered by multidisciplinary 
professionals working in multiple sectors including 
health, education and voluntary organisations.
 Ź Children with all types of speciic phobias and differ-
ent learning abilities are included.
 Ź There are no midpoint outcomes; therefore, the 
study cannot tell whether children improve with 
one-session treatment quicker than with multises-
sion therapy or how the two interventions may work 
in different ways to change outcomes (mechanisms 
of action). However, the study includes longer term 
outcomes which are useful in evaluating sustained 
effect, if any, of the intervention.
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personal distress6 and interference in day-to-day activities.7 
Cognitive– behavioural therapy (CBT) is the dominant 
therapeutic intervention for specific phobias8 9 within 
health services in the UK. Robust evidence supports the 
efficacy of CBT for anxiety disorders in general,10–12 and 
for specific phobias in particular; however, CBT can be 
time consuming, costly and difficult to access because it 
is delivered over multiple sessions during several weeks 
or months by therapists that have received lengthy 
training.13–16 
Alternative methods of CBT delivery, like one-session 
treatment (OST),17 can be used to reduce demands on 
therapist time and associated costs, prevent therapeutic 
drift, and ultimately help children recover quicker.18 19 
OST is a variant of CBT, delivered in a single 3-hour session. 
A central feature is graded exposure where the subject 
comes into proximity with the phobic stimulus in a series 
of graduated steps (from the easiest to the most diffi-
cult). For example, graded exposure for a phobia of dogs 
might first involve looking at pictures of dogs, followed by 
videos of dogs, then by observing dogs in a local park at 
a distance and finally by interacting with dogs first hand. 
OST has been shown to be clinically effective in chil-
dren.20–22 For example, Ollendick et al20 randomised 196 
children (ages 7–16) with phobias to one of three groups: 
(1) OST, (2) an education support group or (3) a wait-
list control group. OST was superior to both comparators 
as measured by improved phobia severity, percentage of 
children who were diagnosis free, and child-related and 
parent-rated anxiety and treatment satisfaction postin-
tervention and at 6 months follow-up. However, to our 
knowledge, OST has not been compared with the current 
‘gold-standard’ approach to specific phobias (ie, CBT), 
and has not been trialled in the UK within the National 
Health Service (NHS).
The present research is a non-inferiority, parallel group 
randomised controlled trial comparing the clinical and 
cost-effectiveness of OST versus CBT for specific phobias 
in children and young people ages 7–16 years old. The 
primary aim is to test whether OST is non-inferior (ie, 
produces similar clinical benefits) to multisession CBT in 
helping children with their specific phobia(s), and the 
wider impact their phobia(s) have on mental health and 
quality of life. A nested qualitative evaluation will explore 
whether OST is acceptable to children, their parents and 
the practitioners who deliver OST. Finally, an economic 
evaluation will examine whether OST offers good value 
for money to the NHS and society compared with multi-
session CBT.
MEthods And AnAlysIs
Participants
The present research will recruit children and young 
people aged 7–16 years old with one or more specific 
phobias, as defined by the Diagnostic and Statistical 
Manual of Mental Disorders, Fifth Edition 10 Add Depart-
ment of Rheumatology.1 The DSM-IV criteria are: (1) 
marked and out-of-proportion fear to a specific object or 
situation, (2) exposure to the feared object or situation 
provokes immediate anxiety, (3) the phobic situation is 
avoided where possible, (4) the avoidance or distress asso-
ciated with the phobia interferes with the person’s routine 
or functioning (eg, learning, sleep, social activities) and 
(5) the phobic avoidance or distress is present for 6 
months or more. We include all types of phobias where 
we can introduce or safely simulate the stimulus for the 
purpose of exposure therapy. We exclude children who 
have conditions that are often referred to as ‘phobias’ but 
are not specific phobias (eg, social or separation anxiety 
referred to in some circumstances as ‘school phobia’) or 
when children need a different intervention as a priority 
(eg, for psychosis or self-harm).
design
This is a non-inferiority randomised controlled trial that 
compares clinical outcomes of OST with those of multises-
sion CBT at 6 months postrandomisation. Nested within 
this trial is an economic evaluation of the cost-effective-
ness of OST against CBT for outcomes and costs over 6 
months. Interviews evaluate perceptions and experiences 
of OST by children, parents and practitioners also at 
6-month follow-up. An internal 9-month pilot determines 
feasibility of recruitment and retention, and monitors the 
occurrence of any adverse events.
recruitment
Our recruitment strategies follow routine care pathways 
for children with specific phobias. These pathways differ 
across our participating sites, which include NHS Trusts, 
Local Authorities and voluntary agencies across England. 
We have mapped the care pathways in each geographical 
area and we promote the study within teams of profes-
sionals who routinely receive referrals of children with 
specific phobias, such as Child and Adolescent Mental 
Health Services (CAMHS), Children’s Hospitals, youth 
services and schools. We also draw attention of the study 
to potential participants through public adverts, for 
example, in local newspapers and posters in general prac-
titioner (GP) surgeries.
randomisation
Following written consent and completion of the base-
line measures, random allocation to treatment groups 
is carried out remotely through a secure web-based 
programme designed by the Sheffield Clinical Trials 
Research Unit (CTRU). The randomisation allocation 
ratio is 1:1 to facilitate equal sample sizes across both 
the OST and CBT groups. Randomisation is stratified 
according to two age groups (7–11 years old vs 12–16 years 
old) and two phobia severity groups (mild to moderate 
vs severe); we use random permuted blocks of variable 
size to ensure enough participants are allocated evenly to 
each arm of the trial within each stratum.
blinding
Complete concealment of allocation, ‘blinding’, from both 
participants and researchers in studies of psychological 
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interventions is often extremely difficult, and, at times, 
impossible.23–26 Our study takes a number of steps to facil-
itate blind assessment of outcomes as a way of reducing 
bias. First, the research assistants collecting baseline 
and follow-up outcomes are independent of the practi-
tioners delivering the interventions. Second, the research 
assistants are not informed of the participants’ group 
allocation and are not involved in the therapy sessions. 
Participants are explicitly reminded not to disclose to 
the research assistant their allocated group. In the event 
of these procedures being compromised (eg, a research 
assistant learning the participant’s allocated group), we 
record this and arrange for a different outcome assessor 
in the future wherever possible. The trial statisticians and 
health economists are blind to treatment allocation while 
the trial is ongoing.
Interventions
One-session treatment
OST is a variant of CBT, but rather than being delivered 
in weekly 45–60 min sessions as in conventional CBT, OST 
is delivered in a longer single session (approximately 
3 hours). Prior to the single session, a 1-hour assessment/
planning session takes place during which the practi-
tioner carries out an assessment in order to plan the treat-
ment session. This involves:
1. Determining the nature, history and associations of 
the phobia.
2. Determining any maintaining factors for the phobia 
(eg, what the child avoids, what safety behaviours she/
he engages in, how friends and family may collude with 
the phobia).
3. Collecting information about the child’s cognitions in-
cluding catastrophic thoughts (eg, what do you think 
may happen if…, what goes through your mind when 
you…).
4. Generating a fear hierarchy (ie, a ‘ladder’ of situations 
or objects that the child avoids because of their pho-
bia, in the order of the fear or anxiety evoked, starting 
from the least frightening).
5. Explaining what is involved in treatment and that the 
exposure tasks are graded and negotiated in every step 
of the way and that nothing will ever happen without 
the child’s permission.
The single session combines graded exposure, partici-
pant modelling, reinforcement and cognitive challenges. 
The main principle of graded exposure is that the child 
gradually confronts the situations from their fear hier-
archy and remains in each situation until their anxiety/
fear subsides at least by 50%. In participant modelling, 
the therapist first demonstrates to the child how to 
interact with the phobic object and then helps the child 
gradually approach the phobic object by joint approaches 
with the therapist gradually fading involvement. Rein-
forcement from the therapist may take the form of social 
praise, encouragement. Finally, the therapist uses the 
exposure tasks as means for actively eliciting, challenging 
and testing negative cognitions or catastrophic thoughts 
associated with the feared situation and by promoting 
positive cognitions in phobic situations. It is important 
that the child maximises, maintains and generalises their 
gains from graded exposure by practising self-directed 
and parent/carer supported exposure tasks at home for 
the ensuing weeks. Maintenance tasks include a commit-
ment to refrain from avoiding or escaping from feared 
situations and to deliberately engineer or enter a feared 
situation regularly.
Cognitive–behavioural therapy
CBT helps people to change unhelpful beliefs and 
behaviours arising in feared situations, such as cata-
strophic thinking and safety behaviours. Interventions 
based on CBT are the dominant model of treatment for 
specific phobias, and are supported by a robust literature 
attesting to its efficacy.8–12 CBT interventions are often 
delivered in 45–60 min sessions every week or fortnight 
over several weeks or months. Each CBT session takes 
the form of structured discussions with a therapist, has 
a specific agenda and sets homework tasks for the child 
or young person between sessions. CBT for children 
and young people with specific phobias aims to help the 
child/young person to: (1) recognise anxious feelings and 
bodily reactions to anxiety; (2) gradually confront their 
feared situations until their anxiety subsides; (3) capture 
and challenge anxious thoughts when faced with a phobic 
situation or object; (4) challenge avoidance behaviours, 
or behaviours that maintain or reinforce the phobia and 
(5) develop coping strategies and anxiety management 
techniques if distress and physical responses to anxiety 
are overwhelming. There is no recommended number of 
CBT sessions for specific phobias but it can vary between 
4 and 20 sessions.
Fidelity to the interventions
Practitioners responsible for specific phobia treatment 
across the recruiting centres will be trained in OST during 
a day’s workshop, with senior practitioners (eg, trained 
therapists) attending a modified half-day training on OST 
and a half-day training on supervising and training others 
in OST to be able to offer continuous support and super-
vision to junior colleagues. OST and CBT sessions are 
audio recorded whenever possible with consent from the 
child and parent. A random selection of 15% of partic-
ipants at each site (or the nearest whole number) has 
one of their sessions (whether OST or CBT) reviewed by 
a supervisor at quarterly intervals. Supervisors score the 
recorded sessions to assess therapist fidelity to OST and 
CBT using the OST Rating Scale 27 and the CBT Scale 
for Children and Young People,28 respectively. This is to 
make sure that CBT principles are applied in both treat-
ment arms. These are used in supervision to improve 
fidelity to the intervention and address training needs for 
the therapists as per usual practice.
outcome measures
We are collecting demographic information (eg, age, 
gender, etc) from all children/young people and their 
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parents. Children and parents are also asked if they have 
a treatment preference at baseline, although this does 
not affect their randomisation in any way. Participants 
complete the following measures at baseline and then at 
6 months follow-up.
Behavioural avoidance task
The primary outcome is the behavioural avoidance task 
(BAT) at 6 months postrandomisation. The BAT is a 
widely used measure of treatment outcomes for phobias in 
children.6 21 The BATs for the Alleviating Specific Phobias 
Experienced by Children Trial (ASPECT) trial are stan-
dardised for each stimulus and have been found to have 
good test–retest reliability20 29 and strong correlation 
with other outcome measures of anxiety and phobia.30 31 
During a BAT, the child gradually confronts their phobic 
stimulus over 10 predefined steps of increasing difficulty; 
the child does not have to complete all the steps. For 
example, a child with spider phobia may start the BAT 
at step 0, standing outside of a room that has a spider 
contained in a box. Subsequent steps the child may take 
are: opening the door (step 1), passing through the 
doorway (step 2), through to holding the spider for 20 s 
(step 10). The number of steps the participant takes is 
the main unit of measurement recorded for analysis. The 
BAT also includes a measure of subjective units of distress 
whereby the child reports their level of fear at the start 
of the BAT, and at the last step completed (ranging from 
0=no fear at all to 8=extreme fear).
The anxiety disorder interview schedule for children and parents
Anxiety disorder interview schedule (ADIS)32 is a well-es-
tablished semistructured interview3 32 33 that obtains infor-
mation from both the child and their parent/carer about 
the type of specific phobias experienced (eg, animal/
insect, small spaces, blood/injection phobias, etc), the 
degree of associated fear (rated from 0=not at all to 
8=very, very much), whether the phobia causes avoidance 
(rated as ‘yes’ or ‘no’) and interference with daily life 
(rated from 0=not at all to 8=very, very much).
Child Anxiety Impact Scale for children and parents
The Child Anxiety Impact Scale for children and parent 
(CAIS-C/P)34 collects information as to what extent 
feeling ‘nervous, anxious or afraid’ impacts on the 
daily life of the child. The child and the parent inde-
pendently rate, on a 4-point scale ranging from 0=not 
at all to 4=very much, 27 statements grouped in 3 subdo-
mains: school activities (eg, getting to school on time in 
the morning), social life (eg, making new friends) and 
home/family life (eg, getting ready for bed at night).
The Revised Children’s Anxiety and Depression Scale
The Revised Children’s Anxiety and Depression 
Scale-C/P (RCADS-C/P)35–38 comprises 47 items to 
capture separation anxiety disorder, social phobia, gener-
alised anxiety disorder, panic disorder, obsessive compul-
sive disorder and major depressive disorder. Children 
state the frequency of which statements such as ‘I worry 
about things’, I have trouble sleeping’ and ‘I feel I will 
make a fool of myself in front of people’ relate to them on 
a 4-point scale: 0=never, through to 1=sometimes, 2=often 
and 3=always.
EQ-5D-Y
The EQ-5D-Y, originally developed by the EuroQoL 
group,39–41 is a widely used measure of health-related 
quality of life in children and young people. Children 
and young people are able to classify their own health 
on a 3-point scale, 1=no problems, 2=some problems 
and 3=a lot of problems, over five dimensions: mobility 
(walking about), looking after myself, doing unusual 
activities, having pain or discomfort and feeling worried, 
sad or unhappy. Additionally, the EQ-5D-Y includes a 
Visual Analogue Scale where participants can indicate 
their overall health status from 0 (worst imaginable state) 
to 100 (best imaginable state). All questions refer to the 
participant’s health state ‘today’.
Child Health Utility 9D
The Child Health Utility 9D (CHU-9D) is a health-re-
lated quality of life measure validated for children and 
young people.42 43 Participants select a sentence from a 
possible five to describe how they feel today in relation 
to a number of constructs (ie, sadness, tiredness, pain, 
etc). For example, participants are asked to select one 
of five statements that best reflects how worried they feel 
ranging from ‘I don’t feel worried today’ to ‘I feel very 
worried today’.
Goal-based outcome measure
A goal-based outcome measure is a method of comparing 
how far a participant feels they have moved towards 
reaching a specific goal they have set before the interven-
tion has begun. A goal-based outcome measure based on 
recent guidelines44 will be used to set up to three goals at 
baseline, with progress towards meeting these goals rated 
on a 10-point scale at the 6-month follow-up point. Prog-
ress can range from 0 (ie, goal not met), to 5 (ie, halfway 
to reaching the goal), through to 10 (ie, goal reached). 
For example, a participant with a dog phobia may set as 
their goal that they would like to be able to spend teatime 
at their grandmother’s house where there is a dog.
Resource Utilisation Questionnaire
We developed a bespoke questionnaire to assess use of 
healthcare and other resources, based on a previous 
Resource Utilisation Questionnaire by Barrett and 
colleagues45 and its adaptations for younger populations 
by members of our research team45–47 The questionnaire 
is completed by the parent and collects data on resource 
and service utilisation relating to the child over the 
previous 6 months on: general health and community 
service use (ie, appointments with GP’s, nurses, social 
services and educational services); mental health service 
use (ie, appointments with a psychiatrist, psychothera-
pists, psychologists, CAMHS therapists and other forms 
of mental health support); hospital-based services (ie, 
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visits to A&E, urgent care centres and hospital stays); days 
missed from school by the child; days missed by parents/
carers from work or studies.
statistical analysis
Sample size
The proposed sample size and non-inferiority margin are 
based on two separate Cochrane reviews looking at the 
effects of psychotherapy for those experiencing anxiety. 
First, Wolitzky-Taylor et al47 conducted a review on studies 
that used both observer-rated BAT-like assessments and 
self-report questionnaires on adults with specific phobias 
and reported an overall, large effect size of d=0.81. 
However, as the treatment may have a different effect on 
children, we also examined the review of Reynolds et al.48 
This review was conducted on studies of children with 
specific phobias but used self-report questionnaires 
rather than observer-rated BATs. The review reported 
a large effect size (d=0.85) for multisession CBT. Prior 
meta-analyses suggest that a standardised mean difference 
of around 0.8 on the BAT scale is clinically important. 
Therefore, we set the non-inferiority margin to be half 
of this at 0.4.49 Assuming a correlation of 0.5 between 
baseline and final BAT measure, we would require 200 
participants (100 in each arm) to have 90% power with 
a 2.5% one-sided significance level to demonstrate 
non-inferiority of OST compared with CBT. The therapy 
is delivered by therapists who will see approximately 15 
patients each and we anticipate a weak therapist effect 
(intraclass correlation coefficient=0.01). This clustering 
will lead to a design effect of 1.14 which increases the 
number required per arm to 114. We further assume a 
20% drop-out rate suggesting that total number of 286 
children and young people (143 per arm) will need to be 
recruited to the study to demonstrate non-inferiority of 
OST compared with CBT.
Data analysis
As this trial follows a randomised, parallel group, non-in-
feriority design, data will be analysed and reported 
according to both Consolidated Standards Of Reporting 
Trials (CONSORT) guidelines50 and the non-inferiority 
trials CONSORT extension.51 Baseline data, including 
demographic characteristics (eg, age, gender) and clin-
ical measures (eg, BAT, RCADS), will be reported between 
the two randomised groups. Jones et al49 recommend both 
per-protocol and intention-to-treat (ITT) analyses for 
non-inferiority designs. For an equivalence or non-inferi-
ority trial, as opposed to a comparative trial, ITT analyses 
are not considered conservative, as any blurring of the 
difference between the treatment groups increases the 
chance of declaring equivalence. We follow this recom-
mendation with the refinement that the main analysis of 
the primary outcome will be per protocol (or completers 
only) with a sensitivity analysis on the ITT population.49 
We will require both the per-protocol and ITT analyses 
to demonstrate conclusive evidence to declare that OST 
is ‘non-inferior’ to multisession CBT. If the results of the 
analysis are discrepant (eg, the ITT rejects the null of 
inferiority but the per-protocol analysis does not or vice 
versa) then we will report the conflicting results from 
both analyses highlighting the inconclusive nature of the 
results. For the sake of the analysis, a participant in the 
OST group is defined as per protocol if they attend both 
the initial functional assessment and the rapid exposure 
therapy session. A participant in the CBT group is defined 
as per protocol if they attend at least four CBT sessions.
The primary outcome (mean BAT score at 6 months) 
and the secondary outcomes (ADIS, CAIS, EQ-5D-Y, 
CHU-9D, RCADS and goal-based outcome scores) will 
be compared between groups using mixed-effects linear 
regression with exchangeable correlation to allow for the 
clustering of outcomes within therapist. The analysis will 
be conducted controlling for baseline BAT score, site 
and stratifying variables (age group and baseline phobia 
severity). The null hypothesis of inferiority will be rejected 
if the two-sided 95% CI for the difference is wholly below 
0.4 (the range of clinical non-inferiority).
We anticipate some drop-out/attrition, so case missing 
data may be an issue. Case and item missing data will be 
examined and multiple imputation methods will be used 
to reduce bias due to any missing responses in both the 
per-protocol and the ITT analyses. Where appropriate, 
modelling methods that generate robust SEs in the pres-
ence of missing data will be considered.
Economic evaluation
We are conducting an economic evaluation from the UK 
personal and social services perspective. This will take 
the form of a within-trial cost–utility analysis to deter-
mine the incremental cost per unit of quality-adjusted 
life years (QALYs) of OST compared with CBT in chil-
dren with specific phobias. Costs will be calculated based 
on: (1) resources required to deliver the intervention 
and (2) individual-level use of health and social services 
by children and absenteeism from school for children 
or from work because of childcare for parents over the 
study period. Resource use will be multiplied by unit costs 
to arrive at total cost in each arm. QALYs will be calcu-
lated by measuring health-related quality of life using the 
self-reported EQ-5D-Y over the study period.
The resources required to deliver the OST interven-
tion will be calculated using bottom–up estimation of the 
time spent by professionals as well as other resources used 
(including phobic stimulus acquisition, ie, animal hire). 
Individual-level service use data will be based on self-re-
ported use of primary and secondary healthcare as well 
as social care using a standardised Resource Utilisation 
Questionnaire. Unit costs of health and social service use 
will be obtained from the UK national database of refer-
ence costs department of health,52 and the Unit Costs of 
Health and Social Care report produced by the Personal 
Social Services Research Unit.53 The cost of medication 
will be based on the most recent version of the British 
National Formulary Royal Pharmaceutical Society of 
Great Britain.54
 o
n
 16 O
ctober 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-025031 on 17 August 2018. Downloaded from 
6 Wright BD, et al. BMJ Open 2018;8:e025031. doi:10.1136/bmjopen-2018-025031
Open access 
Individual-level responses on the EQ-5D-Y will be used 
to estimate health-related quality of life based on a UK 
population valuation set. Subsequently, an area under 
the curve approach will be used to calculate QALYs for 
each child. QALY is a utility-based measure, that is, it 
measures each person’s health state in terms of quality of 
life dimensions and then weights it on the value or utility 
of the health state based on UK population preferences.55
The primary economic analysis will be cost–utility anal-
ysis conducted over the trial follow-up period (6 months). 
Total costs, including the intervention cost and service 
utilisation costs, and QALYs, will be compared between 
the two interventions. Unadjusted costs and outcomes 
will be presented in a descriptive analysis using para-
metric and non-parametric tests. The statistical analysis 
will compare mean costs and QALYs using a regression 
model. The regression analysis will control for baseline 
differences in utility.56 The specification of the model 
will follow the approach recommended by Glick et al57 
which considers the distribution of the dependent vari-
able as well as any correlation between the cost and QALY 
outcomes. The regression coefficient on treatment will 
then represent the difference in mean cost and mean 
QALYs between groups. A bootstrap method will be used 
to produce CIs around the cost and QALY differences 
due to the likely skewness in the distribution of regression 
residuals.58 To present this in the UK decision-making 
context, the results will be in the conventional form of a 
cost-effectiveness acceptability curve (CEAC). CEAC pres-
ents the probability of the intervention being cost-effec-
tive over a range of willingness-to-pay (WTP) thresholds 
per QALY.59 The higher the probability, the more likely 
it is that the treatment is cost-effective at the particular 
WTP threshold.
The following sensitivity analyses will be conducted; 
(1) a cost–utility analysis using the CHU-9D instrument 
instead of EQ-5D; (2) a cost-effectiveness analysis using 
a phobia-specific measure instead of a utility-based 
measure and (3) cost–utility analysis from a health 
services perspective.
nested qualitative evaluation
We will invite a subsample of trial participants to partic-
ipate in individual semistructured interviews and use 
maximum variation sampling to ensure a spread of 
participants differing in age, gender, socioeconomic 
background and type of phobia. We will obtain written 
consent (and assent where appropriate) to interview a 
sample of (1) children receiving OST, (2) their parents/
guardians and (3) practitioners delivering OST across 
all study sites. With parental consent we will recruit and 
interview parents and children separately. Joint parent–
child interviews will be included where participants 
prefer. The final sample size for the interviews in each 
participant group will be determined by data saturation, 
that is, the point where no new themes, ideas and/or 
concepts emerge. Based on a previous nested qualitative 
evaluation of patient acceptability of brief psychological 
interventions,60 we estimate that we will need to complete 
a maximum of 30 interviews with parents, 25 with chil-
dren and 15 with practitioners.
Interviews with children and their parents will be 
conducted after participants have completed the final 
outcome measures at the 6-month follow-up point. 
Interviews for parents will focus on phobia experiences, 
personal and family impact, perceived treatment need, 
treatment expectations and treatment acceptability (eg, 
content, delivery mode, format, setting and facilitation). 
Child interviews will focus on the same topics, adapted 
for age and developmental maturity. Face-to-face inter-
views with children will draw on the principles of ‘draw 
and write’ techniques, whereby children will be offered 
an opportunity to draw a picture relating to their experi-
ences as a prompt to initiate more in-depth discussion.61 62 
Child interviews will last a maximum of 30 min and parent 
interviews a maximum of 60 min, with total time guided 
by the interviewees. Clinician interviews will last for a 
maximum of 60 min and focus on their experiences and 
views of delivering OST, the individual and organisational 
support required and the perceived suitability OST for 
their patient group.
Interviews with parents and older children (13 years 
plus) will be conducted face to face in treatment settings 
or at participants’ homes or via the telephone, depending 
on participant preference. Interviews with younger chil-
dren (12 years and under) will be conducted face to 
face in treatment settings or at participants’ homes, 
depending on participant preference. Practitioner inter-
views will take place face to face in their workplace or over 
the telephone once their own involvement in the trial is 
complete.
All interviews will be digitally recorded and transcribed 
verbatim. Analysis will follow a qualitative framework 
approach,63 a widely used method of analysing primary 
qualitative data pertaining to healthcare practices with 
policy relevance.64 Framework analysis permits both 
deductive and inductive coding, enabling potentially 
important themes or concepts that have been identified 
a priori to be combined with additional themes emerging 
de novo.
Data coding will be undertaken independently by two 
trained researchers. We will additionally train a patient 
and public involvement (PPI) representative to code 
alongside these researchers to ensure coding takes 
account of potential differences in perspective. Coders 
will meet regularly to develop a shared coding manual 
and to ensure that all emerging codes remain grounded 
in original data. An Excel spread sheet will be developed 
which will incorporate preliminary framework themes 
as column headings and the demographic information 
related to participants who provided data under each 
theme. As the constant comparison of new data occurs and 
the coding team’s understandings of the themes under 
consideration develop, the framework will be amended 
and reshaped to enable the introduction of new codes 
and/or the deletion of redundant, similar or otherwise 
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compromised codes. In this way, a final framework will be 
achieved that is considered representative of the entire 
dataset. We will code data from each stakeholder group 
(children, parents/guardians and practitioners) sepa-
rately before comparing and contrasting data findings 
across groups. The final coding manuals for each partici-
pant group will be presented with example entries, to the 
project’s advisory committees to confirm validity, coher-
ence and conceptual relevance.
PublIC And PAtIEnt InvolvEMEnt
The research protocol was developed in partnership 
with service user groups and was reviewed in terms of 
both feasibility and relevance. In addition to this, the 
views of relevant charitable organisations were sought 
and a representative from the Triumph Over Phobia UK 
support group is a coapplicant on this application. We 
have consulted with PPI representatives about their views 
on the full research proposal and how best to involve 
patients throughout the proposed project. In particular, 
we have discussed comments after the first round appli-
cation with representatives of Triumph Over Phobia. 
This includes issues around the non-inferiority design, 
how to measure fidelity and contamination. We have also 
engaged the York Youth Council, who have commented 
on this application and discussed the methodology of 
the trial and the potential impact of the therapy on the 
community. We see PPI as central to our research. A 
representative from Triumph Over Phobia is on our trial 
management group (TMG) and actively involved in the 
planning and delivery of this research. Applicants KL and 
PB are named applicants (PI and Co-PI, respectively) on 
a National Institute for Health Research (NIHR)-funded 
programme grant seeking to improve user involvement 
in mental healthcare planning. This programme has 
been recognised by the former Mental Health Research 
Network (MHRN) for exemplary carer involvement. 
Applicant PB has substantial experience of training users 
and carers in research methodologies, interviewing skills 
and qualitative data analysis. We recognise the need for 
independent qualitative data analysis, and will train a 
service user researcher. The service user representative 
will be reimbursed for their time, commensurate with 
current INVOLVE guidelines.
EthICs And dIssEMInAtIon
obtaining informed consent from participants
As all participants in this study are aged 16 or under, 
consent is required from both a person with parental 
responsibility, and the participant themselves if they are 
deemed competent to do so. Where a child is not deemed 
competent to give full informed consent, we take parental 
consent and seek assent from the child. Prior to the 
consent meeting, the parents and the children receive 
information about the study and have the opportunity 
to discuss any questions or concerns with members of 
the research team. Two age-specific versions of the child 
information sheets are available: one for those aged 7–11 
years and one for those aged 12–16 years. All informa-
tion leaflets and consent forms are codeveloped by the 
research team and PPI representatives to ensure accept-
ability among participants. If a participant wishes to with-
draw from their allocated intervention, we check whether 
they are still agreeable to participate in the planned 
follow-up assessment at 6 months, so that their outcomes 
can be included within our ITT analysis.
data management
Trial data are extracted from source documents and 
entered onto the CTRU’s in-house data management 
system (Prospect). Prospect stores data in a PostgreSQL 
database hosted by the University of Sheffield. The data-
base uses industry standard techniques to provide security, 
including password authentication and encryption using 
Secure Sockets Layer (SSL) /Transport Layer Security 
(TLS). Access to Prospect is controlled by user names and 
encrypted passwords. A comprehensive privilege manage-
ment feature ensures only the minimum amount of data 
required is available to each individual to complete their 
tasks. The system has a full electronic audit trail and is 
regularly backed up. Access to data is restricted to users 
with appropriate privileges only. All data are collected 
and retained in accordance with the Data Protection Act 
1998 and Sheffield CTRU standard operating procedures 
(SOPs).
research governance and conduct of the trial
Trial monitoring procedures and site monitoring are 
undertaken at a level appropriate to a risk assessment 
performed by the Trial Sponsor (Leeds and York Part-
nership NHS Foundation Trust, 2150 Century Way, 
Thorpe Park, Leeds, LS15 8ZB) and the Sheffield CTRU. 
Three committees govern the conduct of this study, in 
accordance with Sheffield CTRU’s SOPs: a trial steering 
committee (TSC), an independent data monitoring and 
ethics committee (DMEC) and a TMG.
The TSC consists of an independent chair, an indepen-
dent subject specialist, an independent clinical academic, 
an independent statistician and a patient representative. 
The TSC meets approximately every 6 months from the 
start of the trial. The DMEC consists of an independent 
chair, an independent statistician and an independent 
ethics specialist experienced in research with children 
and families. The TMG comprises the coapplicants and 
the two trial managers who are jointly supervised by the 
Chief Investogator (CI), the director of the Sheffield 
CTRU and a lead trial manager in the CTRU. Meeting 
attendance of the coapplicants depends on each meet-
ing’s agenda and relevance to their role.
Adverse events
An adverse event monitoring form is used to record any 
untoward occurrence affecting the participant after each 
therapy session by the therapist and at follow-up by the 
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research assistant. Such an event can be directly related, 
possibly related or unrelated to the intervention. An 
occurrence is recorded if it is suspected to be related to 
the intervention or an aspect of the research procedures; 
the therapist assesses relatedness and research assistants 
seek advice from the site principal investigator. The occur-
rence of adverse events during the trial is monitored by 
the trial oversight and management groups, particularly 
the DMEC and the TSC. All adverse events are assessed 
for seriousness, and will be recorded as a serious adverse 
event) if they are life threatening, or require hospitalisa-
tion or prolongation of existing inpatient stay, or result in 
persistent or significant disability or incapacity or death.
No pharmaceutical compounds or medical devices are 
used in this trial, therefore, clinical trials authorisation is 
not required.
dissemination of the research indings
We will publish the study’s findings in peer-reviewed 
academic journals and present at local, national and 
international conferences where possible. Furthermore, 
we will publish a short summary of the results on the 
ASPECT study website that can be accessed by all trial 
participants as well as relevant interest groups, including 
patient groups. Finally, towards the end of the trial, our 
PPI representatives will organise a meeting with stake-
holders including parents and professionals working with 
young people with anxiety disorders to specifically discuss 
the dissemination of the study findings and put together 
a dissemination plan.
trial status
Protocol V.3, 24/04/17. Recruitment to the trial began in 
June 2017 and is estimated to be completed in July 2019, 
with the final follow-up assessments completed in March 
2020.
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